Skip to main content
Explore URMC

Peanut Allergy Study

Research Question:
Does ligelizumab (QGE031), an injectable, improve allergic reactions to peanuts?

Basic Study Information

This study is designed to determine if there is a way to decrease sensitivity to peanuts in patients with a peanut allergy. There are 3 phases in this study: 1) Screening – 3 visits over to 4 weeks, 2) Treatment – 52-weeks - 17 visits with injections once a month, 3) Follow-up – 4 visits over 4 months. The study will involve skin prick tests/food challenges. You will be reimbursed for your participation. Eligibility: Ages 6-55, diagnosed with a peanut allergy, willing to commit to a partnership with our study team and the researchers at Novartis as we work to help patients with peanut allergy!

Study Reference #: Study00006879

Lead Researcher (Principal Investigator)

Lead Researcher:  Theresa Bingemann

Study Contact Information

Study Coordinator: Allison Leadley
Phone: (585) 275-4640

Additional Study Details

Study Details:
This study is intensive. It lasts for about 17 months and has 24 study visits, including skin prick tests and food challenges. We are looking for subjects dedicated to improving the lives of people living with peanut allergy. Reimbursement is provided for each study visit completed.

Number of Visits:  More than 10
Parking:  Reimbursed
Transportation Coverage:  No
Reimbursement:  Yes
Payment Details:  $1,800 stipend if ALL study visits completed. Partial payment received after each visit.

Learn More About These Conditions

More information about Anaphylaxis

More information about Peanut Hypersensitivity

Want to participate in this study?

This field is required
This field is required
You must agree to be contacted to continue.

Return to Search